RK-33

SKU: orb1300301

Description

RK33 is a first-in-class small molecule DDX3 inhibitor. It induces G1 cell cycle arrest and apoptosis while promoting radiation sensitization in DDX3-overexpressing cells. This compound is a valuable tool for oncology research, particularly in studying DDX3's role in cancer cell proliferation and radiosensitization in vitro.

Research Area

Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1070773-09-9
• MW: 428.44
• Purity: >98%
• Formula: C₂₃H₂₀N₆O₃
• SMILES: COc1ccc(Cn2cnc3c4nc(=O)n(Cc5ccc(OC)cc5)c4ncnc23)cc1
• Target: RNA
• Solubility: Soluble in DMSO (up to 20 mg/ml)

Bioactivity

• In Vivo:
  RK-33 in combination with radiation induces tumor regression in multiple mouse models of lung cancer. RK-33, at the dose used, is non-toxic in SCID mice. RK-33-treated mice do not exhibit any discernable morphological changes.
• In Vitro:
  RK-33 binds specifically to DDX3, but not to the closely related proteins DDX5 and DDX17. RK-33 inhibits cancer growth and radiosensitizes lung cancer cells in a DDX3-dependent manner. RK-33 has no effect on either mitochondrial respiration or ATP generation. RK-33 curbs proliferation and induces apoptosis in a DDX3-dependent fashion. Wnt signaling is mediated by DDX3 and inhibited by RK-33. RK-33 impairs radiation-induced DNA damage repair by inhibiting NHEJ activity.
• Cell Research:
  Healthy, 60-70% confluent MDA-MB-231 cells are transduced with shDDX3 lentivirus particles. Knockdown of DDX3 expression is confirmed both by qRT-PCR and immunoblotting. MDA-MB-231 cells are treated with RK-33 (7.5 μM) for 12 h and harvested for RNA. Microarray experiments are performed.(Only for Reference)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DDX3, RK 33, RK33, RK-33

Compound Identifiers

PubChem CID

46184988